longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

AURA

AURA
----

LongbridgeAI

Top Aura Biosciences Executive Quietly Unloads Shares in Notable Insider Move

Tip Ranks
Jun 17, 2026 at 02:11 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Aura Biosciences CFO Anthony S. Gibney sold 12,824 shares worth $82,330 on June 16, 2026. This insider move coincides with the company completing Phase 3 trial enrollment for belzupacap sarotalocan, with topline data expected in late 2027. Despite recent corporate events like equity financing and leadership changes, TipRanks' AI analyst rates AURA as Neutral due to weak financials, including no revenue and high cash burn.

New insider activity at Aura Biosciences Inc ( (AURA) ) has taken place on June 16, 2026.

Aura Biosciences Inc’s Chief Financial and Business Officer, Anthony S. Gibney, has recently trimmed his stake in the company, selling 12,824 shares of Aura Biosciences Inc stock in a transaction valued at $82,330.

Aura Biosciences shares were influenced by news that it completed enrollment of 108 patients in its Phase 3 trial of belzupacap sarotalocan for early choroidal melanoma, with topline data expected in the second half of 2027. Analyst price target revisions referenced in prior coverage have largely been driven by earlier Q1 results, leadership changes with a new CEO, significant equity financing, and a stock repurchase agreement, which together reshape Aura’s risk, dilution, and funding profile.

Spark’s Take on AURA Stock

According to Spark, TipRanks’ AI Analyst, AURA is a Neutral.

Overall score is held down primarily by weak financial performance (no revenue, widening losses, and heavy ongoing cash burn) and bearish technicals (below major moving averages with negative momentum). Offsetting factors include supportive corporate events that strengthen liquidity and extend the cash runway, while valuation inputs are not very informative due to negative earnings and no dividend.

To see Spark’s full report on AURA stock,
click here.

More about Aura Biosciences Inc

YTD Price Performance: 18.35%

Average Trading Volume: 517,525

Technical Sentiment Signal: Sell

Current Market Cap: $662.7M

Login to unlock1,019characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Aura Biosciences

Aura Biosciences

AURA.US

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--